                         SEQUENCE LISTING

<110>  IDP Discovery Pharma, S.L.
 
<120>  Peptides with anti-cancer activity

<130>  P3539PC00

<150>  EP16382114.3
<151>  2016-03-16

<160>  33    

<170>  PatentIn version 3.5

<210>  1
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 10 via a L 
       birradical which is a -(CH2)3-CH=CH-(CH2)3-

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  1

Arg Gln Arg Arg Asn Xaa Leu Lys Arg Xaa Phe Ala Ala Leu Arg Asp 
1               5                   10                  15      


Gln 
    


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 17 via a L 
       birradical which is a -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  2

Arg Gln Arg Arg Asn Glu Leu Lys Arg Xaa Phe Ala Ala Leu Arg Asp 
1               5                   10                  15      


Xaa 
    


<210>  3
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 17 via a L 
       birradical which is a -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  3

Arg Gln Arg Arg Asn Glu Leu Lys Arg Xaa Phe Phe Ala Leu Arg Asp 
1               5                   10                  15      


Xaa 
    


<210>  4
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 13 via a L 
       birradical which is a -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  4

Asn Glu Leu Lys Arg Xaa Phe Phe Ala Leu Arg Asp Xaa 
1               5                   10              


<210>  5
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 12 via a L 
       birradical which is a -(CH2)3-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  5

Arg Gln Arg Arg Asn Glu Leu Xaa Arg Ala Phe Xaa Ala Leu Arg Asp 
1               5                   10                  15      


Gln 
    


<210>  6
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 13 via a L 
       birradical which is a -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  6

Arg Gln Arg Arg Asn Xaa Leu Lys Arg Ala Phe Ala Xaa Leu Arg Asp 
1               5                   10                  15      


Gln 
    


<210>  7
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  7

Arg Gln Arg Arg Asn Glu Leu Lys Arg Leu Phe Phe Thr Leu Arg Asp 
1               5                   10                  15      


Ile 
    


<210>  8
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 11 via a L 
       birradical which is a -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  8

Ala Pro Lys Xaa Val Ile Leu Lys Lys Ala Xaa Ala Tyr Ile Leu Ser 
1               5                   10                  15      


<210>  9
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this residue binds to residue at position 11 via a L 
       birradical which is a -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  9

Ala Pro Lys Xaa Val Ile Phe Lys Lys Ala Xaa Ala Tyr Ile Leu Ser 
1               5                   10                  15      


<210>  10
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  it corresponds to a compound of formula (III) wherein R11 is  
       CH3; and this residue binds to residue at position 16 via a L 
       birradical which is a -(CH2)3-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  it corresponds to a compound of formula (III) wherein R11 is CH3

<400>  10

Ala Pro Lys Val Val Ile Leu Lys Lys Ala Thr Xaa Tyr Ile Leu Xaa 
1               5                   10                  15      


<210>  11
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  11

Ala Pro Lys Ile Val Ile Phe Lys Lys Ala Leu Ala Tyr Ile 
1               5                   10                  


<210>  12
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  12

Ala Pro Lys Val Val Ile Leu Lys Lys Ala Thr Ala Tyr Ile 
1               5                   10                  


<210>  13
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  13

Arg Arg Arg Arg Arg Arg Arg Ala Pro Lys Val Val Ile Leu Lys Lys 
1               5                   10                  15      


Ala Thr Ala Tyr Ile 
            20      


<210>  14
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  14

Arg Arg Arg Arg Arg Arg Arg Ala Pro Lys Ile Val Ile Ser Lys Lys 
1               5                   10                  15      


Ala Leu Ala Tyr Ile 
            20      


<210>  15
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  15

Arg Arg Arg Arg Arg Arg Arg Ala Pro Lys Ile Val Ile Phe Lys Lys 
1               5                   10                  15      


Ala Leu Ala Tyr Ile 
            20      


<210>  16
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  16

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


Ala Pro Lys Val Val Ile Leu Lys Lys Ala Thr Ala Tyr Ile 
            20                  25                  30  


<210>  17
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  the N(t) is HOC(O)(CH2)2C(O)NH- and the C(t) is -CONH2

<400>  17

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


Ala Pro Lys Ile Val Ile Phe Lys Lys Ala Leu Ala Tyr Ile 
            20                  25                  30  


<210>  18
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  18

Asn Glu Leu Lys Arg Ser Phe Phe Ala Leu Arg Asp Gln 
1               5                   10              


<210>  19
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  19

Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Phe Ala Ala Leu Arg Asp 
1               5                   10                  15      


Gln 
    


<210>  20
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  20

Arg Gln Arg Arg 
1               


<210>  21
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  21

Pro Lys Val Val Ile Leu Lys Lys Ala Thr Ala Tyr Ile 
1               5                   10              


<210>  22
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  22

Ala Xaa Lys Val Val Ile Leu Lys Xaa Ala Thr Ala Tyr Ile Leu Ser 
1               5                   10                  15      


<210>  23
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  23

Ala Pro Lys Val Xaa Ile Leu Lys Lys Ala Thr Xaa Tyr Ile Leu Ser 
1               5                   10                  15      


<210>  24
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  24

Ala Pro Lys Val Val Xaa Leu Lys Lys Ala Thr Ala Xaa Ile Leu Ser 
1               5                   10                  15      


<210>  25
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  25

Ala Pro Lys Val Val Ile Leu Lys Xaa Ala Thr Ala Tyr Ile Leu Xaa 
1               5                   10                  15      


Val 
    


<210>  26
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  26

Ala Pro Lys Val Val Ile Xaa Lys Lys Ala Thr Ala Tyr Xaa Leu Ser 
1               5                   10                  15      


<210>  27
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  27

Ala Pro Lys Val Val Ile Leu Xaa Lys Ala Thr Ala Tyr Ile Xaa Ser 
1               5                   10                  15      


<210>  28
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  28

Ala Pro Lys Ile Val Ile Xaa Lys Lys Ala Leu Ala Tyr Xaa Leu Ser 
1               5                   10                  15      


<210>  29
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  29

Arg Gln Arg Arg Asn Xaa Leu Lys Arg Ala Phe Ala Xaa Leu Arg Asp 
1               5                   10                  15      


<210>  30
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<400>  30

Gln Arg Arg Asn Xaa Leu Lys Arg Ala Phe Ala Xaa Leu Arg Asp 
1               5                   10                  15  


<210>  31
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  it corresponds to a compound of formula (III) wherein R11 is 
       -CH3; and this X residue binds to the X residue at position 9 via
       a L birradical which is -(CH2)6-CH=CH-(CH2)3-

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  it corresponds to a compound of formula (III) wherein R11 is -CH3

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa can be any naturally occurring amino acid

<400>  31

Gln Arg Arg Asn Xaa Leu Lys Arg Ala Phe Ala Xaa Leu Arg Asp Gln 
1               5                   10                  15      


<210>  32
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  32

Arg Gln Arg Arg Asn Glu Leu Lys Arg Ala Phe Ala Ala Leu Arg Asp 
1               5                   10                  15      


Gln 
    


<210>  33
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  peptide

<400>  33

Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Phe Phe Ala Leu Arg Asp 
1               5                   10                  15      


Gln 
    


